View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 3, 2022

NIH to stop enrolment in Phase III ACTIV-2 trial of SAB’s Covid-19 therapy

The trial is being discontinued due to reduction in rates of Covid-19 hospitalisation and mortality.

SAB Biotherapeutics has reported that the US National Institutes of Health (NIH) is halting subject enrolment in the Phase III Covid-19 trial of SAB-185 under the ACTIV-2 Program.

SAB-185 was being analysed as part of the Phase III ACTIV-2 master protocol studying therapies for Covid-19 in people with mild-moderate disease who are at increased risk for progression to hospital admission.

It is a fully-human, specifically targeted, broadly neutralising polyclonal antibody treatment candidate.

SAB attributed the termination of enrolment by NIH to low Omicron-linked Covid-19 hospital admission and mortality rates that made the existing trial design unfeasible statistically.

The decline in hospital admission and mortality rates were the primary endpoints of the Phase III trial.

On meeting the preliminary pre-specified efficacy and safety criteria, SAB-185 was progressed into the Phase III trial. But the independent Data and Safety Monitoring Board (DSMB) advised terminating the trial due to “operational futility.”

Reduced hospitalisation and mortality rates reported lately in the trial prompted the sponsors to conclude that despite the possible efficacy of SAB 185 it would be impossible to show statistically significant clinical efficacy with the current study design.

SAB Biotherapeutics co-founder, president and CEO Eddie Sullivan said: “Our team continuously monitors the evolving pandemic to plan for the further development of SAB-185, focusing on identifying Covid-19 patient groups who could potentially benefit from SAB-185, including the potential for prophylactic or therapeutic use in targeted high-risk populations and in those who will become ill from newly emerging variants, along with the potential development of an injectable formulation. 

“We look forward to analysing data from the ACTIV-2 trial to help inform our future clinical initiatives when it becomes available.”

In October last year, the company dosed the first subject in the Phase III ACTIV-2 trial of SAB-185 to treat Covid-19.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU